Search

CN-122005784-A - Application of humanized DKK-1 monoclonal antibody in preparation of medicament for treating osteoporosis

CN122005784ACN 122005784 ACN122005784 ACN 122005784ACN-122005784-A

Abstract

The invention discloses an application of a humanized DKK-1 monoclonal antibody in preparing a medicament for treating osteoporosis, wherein the light and heavy chains of the humanized DKK-1 monoclonal antibody are shown as SEQ ID NO. 1-2. The animal experiments prove that the humanized DKK-1 monoclonal antibody can remarkably improve the bone density of the lumbar vertebra and the tibia of an osteoporosis model mouse and promote bone growth, and provides a new treatment scheme for treating osteoporosis.

Inventors

  • SONG CHUNLI
  • Yuan Wanqiong
  • XIA WEIBO
  • LI MEI
  • ZHANG DAPENG
  • QIAN WEIZHU
  • HOU SHENG

Assignees

  • 北京大学第三医院（北京大学第三临床医学院）

Dates

Publication Date
20260512
Application Date
20260403

Claims (7)

  1. 1. The application of the humanized DKK-1 monoclonal antibody in preparing a medicament for treating osteoporosis, wherein the light and heavy chains of the humanized DKK-1 monoclonal antibody are shown as SEQ ID NO. 1-2.
  2. 2. The use according to claim 1, which is for elderly people.
  3. 3. The use of claim 1, the use comprising increasing bone density.
  4. 4. The use according to claim 1, comprising increasing bone density of lumbar vertebrae and tibia.
  5. 5. The use according to claim 1, wherein the medicament is an injection.
  6. 6. The use according to claim 5, wherein the medicament is a subcutaneous injection.
  7. 7. The use according to claim 5, wherein the medicament further comprises other pharmaceutical excipients or the medicament is a freeze-dried powder injection.

Description

Application of humanized DKK-1 monoclonal antibody in preparation of medicament for treating osteoporosis Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of a humanized DKK-1 monoclonal antibody in preparation of a medicament for treating osteoporosis. Background Osteoporosis (OP) is a common progressive systemic skeletal disease characterized by a decrease in bone density accompanied by a microstructural disruption, manifested by an increase in bone fragility, which in turn leads to an increased risk of fracture. Currently, bisphosphonates, calcitonin, estrogens and raloxifene are common drugs for the treatment of osteoporosis. However, adverse reactions of these drugs severely restrict their clinical applications, such as hormone-related therapies like estrogens, which maintain bone density but increase the risk of cancer, thrombosis and heart disease, bisphosphonates, which inhibit bone resorption and promote bone formation, but cause gastrointestinal problems like esophageal inflammation and gastric ulcers. Therefore, there is a need to develop more drugs with less adverse effects to control OP. The reported DKK-1 antibodies mainly comprise DKN-01, BHQ-880, DKK1-A2, RH2-18 and Hetero-DS. Wherein DKN-01 is human anti-DKK-1 IgG4 monoclonal antibody developed by LeapTherapeutics, and is used for treating various tumors, such as cholangiocarcinoma, intimal carcinoma, gastric cancer, esophageal cancer, liver cancer, ovarian cancer and prostatic cancer, and is in clinical stage II. BHQ-880 can be used for the treatment of multiple myeloma and osteosarcoma. DKK1-A2 recognizes DKK 1P 20 peptide fragments for use in the treatment of blood and solid cancer cells. RH2-18 can be used for treating postmenopausal osteoporosis. The Hetero-DS can treat postmenopausal osteoporosis and bone fractures. In the prior Chinese patent No. CN119318703B of the inventor, the application of the humanized DKK-1 monoclonal antibody in preparing a medicament for treating Alzheimer's disease is disclosed, and animal experiments prove that the humanized DKK-1 monoclonal antibody can prolong the survival time of mice with Alzheimer's disease, improve the cognitive level of the mice with Alzheimer's disease, improve the memory capacity of the mice with Alzheimer's disease and reduce blood sugar, and the humanized DKK-1 monoclonal antibody has the effect of treating Alzheimer's disease and can relieve senile dementia. From the above, although there have been reports of DKK-1 antibodies acting on osteoporosis, however, the present DKK-1 antibodies have limited improvement effect on osteoporosis, and further studies by the inventors of the present application have found that the humanized DKK-1 monoclonal antibodies have a good effect on treating osteoporosis, thereby completing the present application. Disclosure of Invention In order to solve the problems, the invention provides an application of a humanized DKK-1 monoclonal antibody in preparing a medicament for treating osteoporosis, and specifically provides the following technical scheme: The invention provides an application of a humanized DKK-1 monoclonal antibody in preparing a medicament for treating osteoporosis, wherein the light and heavy chains of the humanized DKK-1 monoclonal antibody are shown as SEQ ID NO. 1-2. In a preferred embodiment of the invention, the application is directed to elderly people. In a preferred embodiment of the invention, the use comprises increasing bone density, in particular increasing bone density of the lumbar spine and tibia. In a preferred embodiment of the invention, the medicament is an injection. In a preferred embodiment of the invention, the medicament is an injection for subcutaneous injection. In a preferred embodiment of the present invention, the medicament further comprises other pharmaceutical excipients or the medicament is a freeze-dried powder injection. The humanized DKK-1 monoclonal antibody provided by the invention has the beneficial effects that animal experiments prove that the humanized DKK-1 monoclonal antibody can remarkably improve the bone density of lumbar vertebrae and tibia of an osteoporosis model mouse and promote bone growth, and a novel treatment scheme for treating osteoporosis is provided. Drawings Figure 1 is a graph showing lumbar bone density statistics of experimental mice,Indicating a statistical difference (p < 0.05),Indicating a statistical difference (p < 0.01),Indicating a statistical difference (p < 0.001). Figure 2 is a graph of tibial bone density statistics for experimental mice,Indicating a statistical difference (p < 0.05),Indicating a statistical difference (p < 0.01),Indicating a statistical difference (p < 0.001). Fig. 3 shows calcein fluorescent labeling results of experimental mouse tibial tissues. Two green bands are seen in the figure, corresponding to the positions of the new bone deposition marked on day 13 and